Analytical Data
-
Gene name
GPIHBP1
- Application
-
Alternative Names
GPIHBP1；HBP1；Glycosylphosphatidylinositol-anchored high density lipoProtein-binding Protein 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8IV16
-
Expression Region
1-160aa
-
AA Sequence
MKALGAVLLA LLLCGRPGRG QTQQEEEEED EDHGPDDYDE EDEDEVEEEE TNRLPGGRSR VLLRCYTCK SLPRDERCNL TQNCSHGQTC TTLIAHGNTE SGLLTTHSTW CTDSCQPITK TVEGTQVTM TCCQSSLCNV PPWQSSRVQD PTGKGAGGPR GS
-
Molecular Weight
17 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GPIHBP1 (Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1) plays a crucial role in lipid metabolism and cardiovascular health. As a membrane protein expressed predominantly in endothelial cells, GPIHBP1 facilitates the uptake of triglyceride-rich lipoproteins, vital for maintaining normal plasma lipid levels. Deficiencies or mutations in GPIHBP1 can lead to severe hypertriglyceridemia, a condition that significantly increases the risk of pancreatitis and cardiovascular diseases. Recent studies have highlighted the importance of GPIHBP1 in the binding and transport of lipoproteins in the lymphatic and circulatory systems. Given its role in lipid homeostasis and disease pathogenesis, GPIHBP1 has emerged as a potential therapeutic target for managing metabolic disorders. The recombinant protein form of GPIHBP1 is being extensively investigated to understand its structure-function relationship, interactions with lipoproteins, and potential applications in drug development, providing insights into its mechanistic roles in lipid transport and metabolism. Through the production and characterization of GPIHBP1 recombinant protein, researchers aim to elucidate the biological pathways influenced by this protein and explore its implications in both health and disease contexts, ultimately paving the way for novel treatment strategies targeting dyslipidemia and associated cardiovascular risks.
